Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
Criminal justice system
Medications for opioid use disorder
Opioid use disorder
Journal
Journal of substance use and addiction treatment
ISSN: 2949-8759
Titre abrégé: J Subst Use Addict Treat
Pays: United States
ID NLM: 9918541186406676
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
09
09
2022
revised:
09
01
2023
accepted:
15
04
2023
pmc-release:
01
06
2024
medline:
22
5
2023
pubmed:
22
4
2023
entrez:
21
04
2023
Statut:
ppublish
Résumé
This study examines social service clinicians' (SSCs) perspectives of factors within the criminal justice system that impact justice-involved individuals' use of medications for opioid use disorder (MOUD). Opioid use disorder (OUD) rates are high among justice-involved individuals, and overdose risk is heightened upon release from incarceration. This study is innovative, as it specifically focuses on criminal justice contexts that influence the MOUD continuum of care from the perspective of clinicians working within the criminal justice system. Understanding criminal justice-related facilitators and barriers to MOUD treatment will guide tailored policy intervention to increase MOUD use and promote recovery and remission among justice-involved individuals. The study completed qualitative interviews with 25 SSCs who are employed by a state department of corrections to provide assessment and referrals to substance use treatment to individuals on community supervision. The study used NVivo software to code the major themes found within each transcribed interview; two research assistants participated in consensus coding to ensure consistency in coding across transcripts. This study focused on the secondary codes that fell under the "Criminal Justice System" primary code, as well as codes that indicated barriers and facilitators to MOUD treatment. SSCs cited sentencing time credits as structural facilitators of MOUD treatment; clients sought more information about extended-release naltrexone since time off of their sentence was available if initiated. Support for extended-release naltrexone by officers and judges was often mentioned as an attitudinal facilitator of initiation. Poor intra-agency collaboration among department of corrections agents was an institutional barrier to MOUD. Also, probation and parole officers' stigma surrounding other types of MOUD, specifically buprenorphine and methadone, was an attitudinal barrier to MOUD within the criminal justice system. Future research should examine the effect that time credits have on extended-release naltrexone initiation, considering the wide consensus among SSCs that their clients were motivated to initiate this type of MOUD because of the resulting time off their sentences. Stigma among probation and parole officers and lack of communication within the criminal justice system need to be addressed so that more individuals with OUD may be exposed to life-saving treatments.
Identifiants
pubmed: 37084815
pii: S2949-8759(23)00101-7
doi: 10.1016/j.josat.2023.209051
pmc: PMC10198928
mid: NIHMS1894738
pii:
doi:
Substances chimiques
Naltrexone
5S6W795CQM
Buprenorphine
40D3SCR4GZ
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
209051Subventions
Organisme : NIDA NIH HHS
ID : R01 DA048876
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no conflicts of interest to report.
Références
JAMA Netw Open. 2020 Feb 5;3(2):e1920622
pubmed: 32022884
Subst Use Misuse. 2018 Dec 6;53(14):2421-2430
pubmed: 29958042
Health Educ Q. 1988 Winter;15(4):351-77
pubmed: 3068205
J Subst Abuse Treat. 2015 Oct;57:75-80
pubmed: 25997674
Addiction. 2016 Apr;111(4):695-705
pubmed: 26599131
Drug Alcohol Depend. 2018 Mar 1;184:57-63
pubmed: 29402680
Int J Ment Health Addict. 2013 Feb 1;11(1):110-122
pubmed: 23956702
Int J Soc Psychiatry. 2021 Nov;67(7):840-853
pubmed: 33380251
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):323-331
pubmed: 27763996
Ann Intern Med. 2013 Nov 5;159(9):592-600
pubmed: 24189594
J Opioid Manag. 2008 Mar-Apr;4(2):81-6
pubmed: 18557164
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Int J Drug Policy. 2020 Jul;81:102768
pubmed: 32446130
BMJ Open. 2023 Mar 20;13(3):e066068
pubmed: 36940952
Addict Sci Clin Pract. 2018 Dec 3;13(1):23
pubmed: 30509314
J Subst Abuse Treat. 2015 Mar;50:50-8
pubmed: 25456091
Subst Abuse Treat Prev Policy. 2021 Feb 22;16(1):19
pubmed: 33618744
Am J Public Health. 2018 Sep;108(9):1207-1213
pubmed: 30024795
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516
Subst Abus. 2012;33(1):9-18
pubmed: 22263709
Subst Abus. 2016;37(1):127-33
pubmed: 26860334
Int J Drug Policy. 2020 Nov;85:102701
pubmed: 32223985
Int J Drug Policy. 2018 Apr;54:9-17
pubmed: 29324253